Summary:
Envoy Medical has secured three new patents in the U.S., Australia, and Hong Kong that expand its global intellectual property portfolio for fully implantable cochlear implant solutions without external components.

Key Takeaways:

  • Innovation in implants: New patents cover advancements in implantable signal processors, electrode impedance diagnostics, and stimulation calibration.
  • Clinical potential: These technologies aim to improve system reliability, precision in stimulation, and overall performance of fully implantable cochlear implants.
  • Global momentum: The expanded international patent portfolio underscores Envoy Medical’s commitment to advancing next-generation, patient-centered hearing restoration solutions, according to the company.

Envoy Medical Inc., a hearing health company focused on developing innovative, fully implanted hearing solutions, announced the issuance of three new patents across the United States, Australia, and Hong Kong. These patents expand the company’s global intellectual property portfolio for cochlear implant solutions that don’t require externally worn components.

The U.S. Patent & Trademark Office has issued the following patent to Envoy Medical:

U.S. Patent No. 12,390,634, on August 19, 2025. The title of the patent is Fully Implantable Modular Cochlear Implant System. This patent relates to cochlear implant systems having a signal processor and an implantable battery and/or communication module having a signal generator that generates digital signals for communicating to the signal processor. The signal processor and the implantable battery and/or communication module include circuitry, a can that houses and surrounds the circuitry, and an impedance between the circuitry and the can to reduce unintended electrical communication between the circuitry and a cochlear electrode of the cochlear implant system.

FDA Approves Envoy Medical’s Study for Fully Implanted Cochlear Implant

The Australian Patent Office has issued the following patent to Envoy Medical:

Australian Patent No. 2022254630, on July 17, 2025. The title is Cochlear Implant System with Electrode Impedance Diagnostics. This patent relates to electrode impedance diagnostics in cochlear implant systems. A cochlear implant system determines an impedance associated with a current path from a source element to a return electrode and determines one or more stimulation parameters for the source element based on the impedance. An example stimulation parameter is a compliance voltage for the source element to provide a prescribed current.

The Hong Kong Patent Office has issued the following patent to Envoy Medical:

Hong Kong Patent No. 40101898, on May 16, 2025. The title is Cochlear Implant Stimulation Calibration. This patent relates to calibrating current flow in a cochlear implant system. A switching network is controlled to place a source element of a cochlear implant system in communication with a testing circuit. An amount of electrical current provided to the testing circuit is determined and the output of the source element is adjusted based on the determined amount of electrical current.

“Our patent portfolio has many critical building blocks to redefine what’s possible for hearing restoration solutions,” says Brent Lucas, CEO of Envoy Medical. “These additional patents strengthen our position. By expanding our global patent portfolio, Envoy Medical is not only protecting groundbreaking innovations, but also supporting our mission to deliver life-changing, fully implantable solutions to more people around the world. This momentum brings us one step closer to eliminating daily limitations faced by millions of people living with hearing loss.”

For more information about Envoy Medical, visit www.envoymedical.com. 

Featured image: Dreamstime